DRUG DELIVERY PLATFORMS

Kinesyx

Kinesyx Logo

Bioactive oligomers which allow for drugs to be coated directly onto the surface of a medical device and the tailoring of the drug release profile depending on therapeutic requirements

The versatile nature of Kinesyx™ technology allows for the coating of various drugs directly onto the surface of a medical device and the tailoring of the drug release profile depending on therapeutic requirements. This can range from a 30 day release from a metallic stent to a 60 second release from a nylon balloon.

ADVANTAGES

TECHNOLOGY ADVANTAGES
  • Surface pacification = reduced thrombogenicity
  • Increased pharmaceutical bio-availablility
  • Programmable release period (sustained over days/weeks or transient over minutes)
  • Bio-elimination properties

PRODUCT APPLICATION

DRUG COATED BALLOON
  • Minimal drug loss in transit
  • Minimal particulates
  • Coating consistency
  • Efficient druge transfer to tissue
  • Strong safety profile

PRODUCT APPLICATION

Drug Coated Balloon

IBI’s current focus is the development of a drug coated balloon (DCB) for peripheral vascular disease in partnership with Qualimed, a German manufacturer of medical devices.

The product under development has a strong safety profile, competitive tissue uptake, consistent coating deposition, low loss in transit, flexibility/pliability and produces minimal particulates. The IQ-1 DCB is expected to begin FIM trials and application for CE Mark in 2017.

Drug Coated Balloon for coronary and peripheral applications →

Kinesyx Case Study
OUS APPROVED COMPETITIVE DCB PRODUCT
Kinesyx Case Study
IBI KINESYX PACLITAXEL COATED DCB
Powered by Innovasium